RFC
NBSE

Russell Frank Company’s NeuBase Therapeutics, Inc. Common Stock NBSE Stock Holding History

Russell Frank Company’s Portfolio NBSE Stock Details NBSE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q2 		– Sell
-102
Closed -$396K – 2875
2014
Q1 		$396K Buy
+102
New +$537K ﹤0.01% 2443

Other funds holding NBSE

VAM
Visium Asset Management New York $1.43B AUM 3.58% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
VM
VHCP Management New York $93M AUM 10.04% 1-Year Est. Return
LOAMU
Lombard Odier Asset Management (USA) New York $957M AUM 35.8% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
KCM
Kennedy Capital Management St Louis, Missouri $4.72B AUM 36.69% 1-Year Est. Return

Russell Frank Company's NBSE Position: Q2 2014 in Review

Russell Frank Company sold out of NeuBase Therapeutics, Inc. Common Stock (NBSE) in Q2 2014, closing a stake of 102 shares — an estimated $396K sold.

Russell Frank Company first reported a position in NBSE in Q1 2014 and held it in 1 quarter. The position peaked at $396K in Q1 2014. 57 funds tracked by Wall St. Rank hold NBSE as of Q2 2014.

  • Russell Frank Company reported no remaining NeuBase Therapeutics, Inc. Common Stock position as of Q2 2014 after selling out during the quarter.
  • Russell Frank Company sold 102 NeuBase Therapeutics, Inc. Common Stock shares in Q2 2014, an estimated $396K.
  • Russell Frank Company first reported a position in NeuBase Therapeutics, Inc. Common Stock in Q1 2014 and held it in 1 quarter.
  • Russell Frank Company's NeuBase Therapeutics, Inc. Common Stock position peaked at $396K in Q1 2014.
  • 57 funds tracked by Wall St. Rank held NeuBase Therapeutics, Inc. Common Stock as of Q2 2014.

Based on Russell Frank Company's 13F filing for Q2 2014, filed 14 Aug 2014.